Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.59 |
| ▸ | PRKCB | P05771 | 9/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915171 | 0.87 | CDK2 (0.64) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL3484573 | 0.87 | PAK4 (0.63) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL4477599 | 0.84 | HPGD (0.42) | PAK4PRKCBAURKA | |
| SCHEMBL2922180 | 0.83 | PRKCB (0.51) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL2915167 | 0.83 | AURKA (0.69) | PAK4CCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2924218 | 0.82 | CCNA2 (0.56) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL1987489 | 0.82 | CCNA2 (0.61) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL3485966 | 0.80 | AURKA (0.70) | CCNA2CDK2CCNA1NTRK1AURKA | |
| SCHEMBL5110745 | 0.80 | CCNA2 (0.72) | PAK4PRKCBCCNA2CDK2CCNA1 | |
| SCHEMBL2913491 | 0.79 | CDK2 (0.47) | PRKCBCCNA2CDK2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | PAK4 259/4885PRKCB 29/4885CCNA2 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.